Session 5: Anti-Diabetes and Anti-Metabolic Disorder Drug Discovery & Development
|
|
Title: Obesity-related orphan GPCRs: Genomics and Informatics Identification Followed by Image-based Cell Screening
Dr. Ralph Garippa, Research Leader , Roche, USA
|
|
Title: Diabetes Mellitus and current pharmacological approach
Dr. Junming Yie , Principle Scientist, Pfizer Global Research & Development, La Jolla , USA
|
|
Title: Enhancing Insulin Action by a Novel Chromium (D-phenylalanine)3 Complex
Dr. Nair Sreejayan , University of Wyoming, USA
|
|
Title: Proteomic and Medicinal Approaches to Diabetes and Its Complications
Dr. William Cho, Scientific Officer, Queen Elizabeth Hospital, Hong Kong, China
|
|
Title: Protein Tyrosine Phosphatase 1B Inhibitors: Synthesis and Evaluation as Anti-Diabetic Agents
Dr. Joong-Kwon Choi, Head, Korea Research Institute of Chemical Technology, Korea
|
|
Title:Incretin mimetics: New Treatment Paradigm in Type 2 Diabetes Mellitus
Dr. Raffaella Balena , M.D., Ph.D., Vicedirectorin, F. Hoffmann-La Roche Ltd, Switzerland
|
|
Title: Regeneration Therapy for Diabetes Mellitus by Plant-derived Bioactive Metabolites
Dr. Kazuo Umezawa, Professor, Faculty of Science and Technology, Keio University, Japan |
|
Title: The Selective Thyroid-Receptor-b Agonist KB-141 Lowers Body Weight and Lipids Without Tachycardia in Primates and Rats
Dr. Gary Grover , Director of Pharmaco, Eurofins-product safety labs, USA
|
|
Home
